August 26, 2022Open Access

Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

SG demonstrated statistically significant PFS benefit over chemotherapy, with a manageable safety profile in patients with heavily pretreated, endocrine-resistant HR+/HER2- advanced breast cancer and limited treatment options.

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Rugo et al. (Fri,) studied this question.

synapsesocial.com/papers/69ddc9eaa051b8e25be93957 https://doi.org/https://doi.org/10.1200/jco.22.01002

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study2011 · 1,097 citations
2New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)2008 · 29,574 citations
3Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA.2021 · 27 citations
4Recommended Guidelines for the Treatment of Cancer Treatment-Induced Diarrhea2004 · 632 citations
5Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline2016 · 647 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo